A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Omega-3 carboxylic acids (Primary) ; HMG-CoA reductase inhibitors
- Indications Cardiovascular disorders; Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Acronyms STRENGTH
- Sponsors AstraZeneca
- 13 May 2019 Planned End Date changed from 31 Oct 2019 to 30 Sep 2020.
- 13 May 2019 Planned primary completion date changed from 31 Oct 2019 to 30 Sep 2020.
- 19 Aug 2018 Trial design published in the Clinical Cardiology